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Despite the fact that the hepatocellular carcinoma (HCC) represents a major health problem, very few interventions are
available for this disease, and only sorafenib is approved for the treatment of advanced disease. Of note, only very few
interventions have been thoroughly evaluated over time for HCC patients compared with several hundreds in other,
equally highly lethal, tumours. Additionally, clinical trials in HCC have often been questioned for poor design and
methodological issues. As a consequence, a gap between what is measured in clinical trials and what clinicians have to
face in daily practice often occurs. As a result of this scenario, even the most recent guidelines for treatment of HCC
patients use low strength evidence to make recommendations. In this review, we will discuss some of the potential
methodological issues hindering a rational development of new treatments for HCC patients.
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Hepatocellular carcinoma (HCC) is the sixth most frequent
tumour and represents the third leading cause of cancer death
worldwide [1]. Differences in HCC risk factors and aetiology
exist among different world regions (i.e. more related to
hepatitis B virus (HBV) in Asian/African countries and to
hepatitis C virus (HCV) and non-infectious in Western
countries) and the incidence of this tumour is increasing
mostly in Western countries along with the spread of HCV
infection. Despite the fact that the HCC represents a major
health problem, very few interventions are available for this
disease. In fact, while potentially curative treatment options are
available to localised disease patients, only one drug is
approved for the treatment of advanced disease. In particular,
the multikinase inhibitor sorafenib has been recently approved
as ﬁrst-line treatment for HCC patients, based on the results of
two separate phase III trials conducted in Western and Asian
countries, respectively [2, 3]. However, even more dismal is the
fact that very few interventions have been thoroughly evaluated
over time for HCC patients compared with several hundreds in
other, equally highly lethal, tumours [4]. Only 16 phase III
trials evaluating systemic treatments for advanced disease are
active by June 2012 (from clinicaltrials.gov—last visit 15th
June), with almost 50% of these evaluating sorafenib in special
populations [there is only one study in Child-Pugh (CP) B
patients] or combined with local treatment. Of the remaining
seven trials three are not restricted to HCC patients.
Additionally, clinical trials have often been questioned for
poor design and methodological issues. As a consequence,
a gap between what is measured in clinical trials and what
clinicians have to face in daily practice often occurs. As a result
of this scenario, even the most recent guidelines for treatment
of HCC patients use low strength evidence to make
recommendations [5].
A seminal paper recently highlighted several factors
potentially contributing to this scenario and tried to establish
the bases of a common framework to improve the clinical
investigation design in HCC [6]. In this review, we will discuss
some of the potential methodological issues hindering a
rational development of new treatments for HCC patients.
clinical development of anticancer drugs
Rational clinical development of new treatments for a
particular tumour follows subsequent phases of investigation
culminating with the regulatory approval. Phase I studies are
usually small studies aimed to ﬁnd the dose and the schedule
for further investigations and to initially evaluate safety. The
optimal design of phase I trials is aimed to minimize the
number of patients treated with low, sub-therapeutic doses of
the drug and those exposed to high, potentially toxic doses.
Phase II trials are primarily aimed at the evaluation of the
activity, tolerability and safety of the experimental drug in a
larger population than in phase I. Other objectives of phase II
trials include the description of the tolerability and the safety
of the drug in a larger population than phase I. Multiple phase
II trials in different tumour populations provide the direction
of the further development by screening the tumour type in
which the design of phase III trials is worthwhile. Randomised
phase II trials are important tools to inform the go/non-go
decision through phase III trials. However, they are far from
being a deﬁnitive comparison between two treatments, nor are
powered to support it. Phase III trials represent the most
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robust and deﬁnitive test of the efﬁcacy (i.e. how the patient
will beneﬁt from the treatment) of a drug in a particular
tumour type. The evaluation of their results in terms of
applicability to the population of patients encountered in
clinical practice and of the extent of beneﬁt the patients can
derive from the treatment strongly relies upon variables such
as study population, end points and study design (internal and
external validity).
The successful progression of a new treatment to the
approval is conditioned by the appropriate and informative
conduction of all the phases. Study population, end points and
study design acquire several peculiarities in HCC. Discussion
about these points will be the main topic of the following
sections.
selection of study population
Rational development of new anticancer targeted therapeutics
moves through testing biological hypotheses, to ﬁnd the drug
levels needed to effectively inhibit the target (proof of principle)
and to demonstrate a meaningful activity in appropriately
selected population (proof of concept) [7]. Recent ﬁndings have
emphasised the importance of selecting patients to treat with a
particular drug in order to maximise the beneﬁt they can derive
from. Epidermal growth factor receptor (EGFR) mutations in
predicting sensitivity to tyrosine kinase inhibitors [8], BRAF
V600 mutation with vemurafenib in melanoma [9] or BRCA1/2
mutations with PARP inhibitors in ovarian cancer [10] are only
few examples of this story started with imatinib and
trastuzumab almost three decades ago.
Early-phase clinical trials represent the moment in which
most of these biological hypotheses are tested [11]. Selection of
patients based on clinical or molecular features in these trials
might foster further research in a particular ﬁeld and test
whether effective target inhibition is achieved at therapeutic
doses as well as address potential pharmacokinetic or
pharmacodynamic variability among patients. Recent data have
demonstrated the feasibility of this approach [12]. In the later
stage of clinical investigation, the appropriate selection of the
study population is fundamental to warrant the transferability
of study results to the general population of patients (external
validity). Several factors contribute in pursuing the rational
selection of the HCC population for clinical trials and these
factors are often critical points in published trials.
With these premises, the factors to be taken into account in
selecting a study population in HCC include the availability of
tissue samples, the prognosis of patients with HCC and the
liver function. Ethnicity and other factors will be also brieﬂy
discussed.
tissue availability and biomarkers
developing
Most predictive biomarkers are tissue-derived; multiple,
sequential biopsies are often required for biomarker evaluation
and validation. ‘Non-invasive’ diagnostic criteria for HCC have
been established in 2005 [13]. Mainly due to the risk of
seeding during the biopsy, quantiﬁed by Stigliano et al. [14],
and to the overall poor level of consensus among pathologists
in the evaluation of the tumour grade, histological diagnosis
has been largely replaced by radiological features [i.e. the
contrast uptake during the arterial phase and rapid washout
during the venous or the delayed phase at computed
tomography (CT) or magnetic resonance imaging (MRI)]. As a
result of this recommendation, very few patients have a tissue
sample at diagnosis and very few studies (only three in the
Physician Data Query database by June 2012; see http://
www.cancer.gov/cancertopics/pdq/cancerdatabase) involving
HCC patients required histological conﬁrmation of the tumour
as inclusion criteria. This paucity of tissue samples for most
HCC patients is clearly a major issue for the rational
development of new targeted agents. In fact, albeit the
evaluation of potential predictive markers of response to
particular targeted agents (i.e. drug target) can be warranted
even with the few patients who have the tissue samples, their
validation requires larger cohorts that are absolutely unrealistic
in this scenario [15].
prognostic evaluation in selecting
patients
Selecting patients with the same prognostic outcome is also
critical to the rational clinical trials design. Generally, the
prognostic evaluation of cancer patients includes both disease
extent assessment and other relevant prognostic variables (i.e.
liver function) [16]. Liver function will be extensively discussed
below. Several staging systems have been proposed. The
Barcelona Clinic Liver Cancer (BCLC) system represents an a
priori stratiﬁcation of HCC patients into four main categories
according to the disease extent, liver function, performance
status (PS), portal pressure and co-morbidities. Although its
prospective external validation is lacking and it includes some
subjective and complex investigations (PS and portal pressure,
respectively), BCLC ﬂow provides a treatment pathway for
patients included in each category [5, 17]. This unique feature
made it the most extensively used staging system both in
clinical practice and in clinical trials. Other systems have been
developed [16]. Among these, the Cancer of the Liver Italian
Programme (CLIP) [18, 19] is widely used worldwide. In
particular, the CLIP score has been retrospectively developed
in a large population of HCC patients [18] and prospectively
validated in an external population of HCC patients [19].
Notwithstanding some limitations (i.e. highest values in
populations where the disease burden at diagnosis is low
thanks to early detection), the CLIP score demonstrated
superiority in prognostic assessment when compared with
other systems like Okuda [19]. However, the validity of each
score against the others is still under debate and as previously
highlighted, with some exceptions, seems strongly dependent
upon the population considered [20]. In this perspective,
ethnicity is another important factor to be taken into account
and it will be discussed later.
liver function
The vast majority of the HCC patients have underlying liver
disease that can ultimately affect the liver function
Annals of Oncology supplement article
Volume 24 | Supplement 2 | April 2013 doi:10.1093/annonc/mdt052 | ii
independently from the HCC. Liver function deserves a
particular consideration in designing clinical trials for patients
with HCC for at least two reasons. First, the prognosis of
severely impaired cirrhotic patients strongly relies upon the
liver function irrespective of HCC [21, 22]. Therefore, given
the worsening prognosis of the transition between
compensated and decompensated cirrhosis, the relative beneﬁt
of a treatment declines as much as the liver function loss
determines the death of the patient rather than the tumour
progression [23]. Second, an impaired liver function alters,
though at variable degrees, the drug tolerability and activity,
potentially due to an altered metabolism of an active
compound (including altered activation of prodrugs). At the
mention of the latter point, a recent phase I trial of sorafenib
in a population of liver and renal function impaired cancer
patients (including 17 HCC patients) found that the
recommended dose of sorafenib decreases with organ function
worsening [24]. In particular, for patients with moderate
[bilirubin >1.5 × ULN to ≤3 × ULN, any aspartate
aminotransferase (AST), albumin normal] to severe (bilirubin
>3 × ULN to 10 × ULN, any AST, albumin normal) up to very
severe (albumin ≤2.5 mg/dl, any bilirubin, any AST) hepatic
dysfunction, the recommended dose ranged from 200 mg twice
a day to <200 mg every third day up to 200 mg once a day,
respectively. Interestingly, the trials did not ﬁnd any signiﬁcant
correlation between sorafenib area under the curve (AUC) and
hepatic function tests (albumin, bilirubin and AST) or
creatinine clearance. A signiﬁcant (P < 0.001) reduction in the
circulating unbound (to the proteins) fraction of sorafenib has
been observed when normal patients have been compared with
patients with both liver and renal dysfunction [24].
The most used system to score the liver function is the CP
score. Patients with chronic liver disease are classiﬁed CP-A to
-C, with CP-A accounting for the less compromised function,
based on the points scored in ﬁve clinical variables: albumin,
bilirubin, prothrombin time, ascites and encephalopathy. In
general, CP-C patients are poor candidates for clinical research,
due to their poor prognosis without liver transplantation.
On the other hand, although CP-A patients represent only a
minority of the patients with advanced HCC candidate to
systemic treatment, the trials aimed to register new treatments
in HCC were restricted to this population [2, 3].
A great debate exists in judging the inclusion in clinical trials
of CP-B patients, which represent a relevant proportion of
those candidates to a systemic treatment [6, 25].
It has been suggested that in these subjects, death-related
cirrhosis prevents from observing the actual antitumour effect
of the tested treatments. Therefore, the clinical development of
new anticancer therapeutics in HCC should be aimed, though
at least initially, to demonstrate the efﬁcacy in the best-
available scenario, thus enrolling only CP-A patients. Only
when a substantial beneﬁt has been demonstrated in these
patients, further investigations in CP-B are warranted [6].
However, one could agree with this process if the initial
focus, in the best-available scenario, would not automatically
terminate with the approval of the new drug to the general
practice. As an example of the latter concept, sorafenib was
approved by both Food and Drug Administration (FDA) and
European Medicine Agency for the ﬁrst-line treatment of HCC
patients independently of CP status, based on the results of
two phase III trials restricted to CP-A [26]. Interestingly, it has
been also said that the approval of sorafenib for HCC patients
irrespective of the CP score has left the oncology community
in a conundrum: a physician has to face the difﬁcult choice
between giving the drug to a CP-B patient without any
deﬁnitive information regarding the potential beneﬁts and
harms to the patient or not to give a drug to the patient,
formally a candidate to receive it and lacking any other
standard treatment option [27]. Moreover, based on the
available data, CP-B patients may gain less survival beneﬁt [28,
29] with higher variability in plasma concentrations of the
drug [28] and an increased probability of drug-related serious
adverse events [29]. Interestingly, the problem of
generalizability has been recognised even at some regulatory
levels as the evidence produced by Abou-Alfa et al., albeit
derived from an open-label phase II trial, has been used by
NICE as a theoretical basis to reject the approval of sorafenib
for HCC patients [30]. It has been suggested to perform ad hoc
trials since evidence from small non-comparative trials
conducted in CP-B patients can underestimate as much as
phase III trials conducted only in CP-A can overestimate the
real beneﬁt gained by ‘real world’ HCC patients treated with
sorafenib.
ethnicity
Ethnicity is a widely accepted risk factor for the development of
HCC [31]. In particular, the prevalence of HCC is much higher
in the Asian population, whose members are more commonly
infected by HBV than in Western ones [32]. However, the
existence of differences in mortality and other HCC-related
factors between ethnic groups is still controversial [31].
In a retrospective study, Wong et al. have assessed the
potential ethnicity based differences in HCC presentation in a
cohort of 276 patients, 162 of whom were Asian-Americans
and 114 were non-Asian-Americans [31]. Overall, when
compared with non-Asian-Americans, Asian-Americans
presented a signiﬁcantly higher incidence of HBV infection
history and family history of HCC. Moreover, Asian-
Americans had lower CP scores (class A: 62.0% versus 31.4%)
and presented with a lower stage of HCC (Okuda staging; I:
43.8% versus 22.8%).
In a wider case–control study (n = 1040), conducted at the
Stanford University Medical Center, Asian ethnicity was
identiﬁed in univariate analysis as an independent risk factor
for the development of HCC in patients with underlying liver
disease [OR, 1.6 versus non-Asian ethnicity; CI 95% (1.2–2.2)],
and this result was conﬁrmed in a multivariate model inclusive
of several risk factors (age, gender, cirrhosis status, Asian
versus non-Asian, AFP ≥50 ng/ml, cumulative cigarette use,
heavy alcohol consumption, aetiology of liver diseases and
diabetes mellitus) [33]. The existence of differences in the risk
and presentation of HCC between Asian and non-Asian
populations is further supported by a recent study of tissue
array analysis: in samples from Asian patients, more frequent
positive staining for p53 (24%) was reported when compared
with the American group (9%) [30]. Conversely, a lower
frequency of positive staining for MDM2 was observed (2%
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versus 26%). These results could lend some support to
differences in the molecular pathogenesis of HCC in different
populations.
Collectively, the above-mentioned ﬁndings suggest that, in
order to enhance the robustness of clinical trials, the included
population should be stratiﬁed according to ethnicity as
necessary.
other factors
Other prognostic factors affecting long-term survival and
treatment outcomes have been tested, and may therefore
potentially represent useful stratiﬁcation criteria in clinical
trials. We brieﬂy report the results of some recent studies
addressing this issue.
Cheng et al., in a study with 879 Taiwanian patients from
1993 to 2005, identiﬁed a lack of tumour encapsulation, AST
values >68 U/l and blood loss >500 ml as independent
prognostic factors for disease-free survival (DFS), whereas a
lack of tumour encapsulation, AST values >68 U/l, blood loss
>500 ml, and serum α-fetoprotein values >200 ng/mL were
independent factors impairing overall survival (OS) [34].
A prospective study with 786 HCC patients who received
locoregional therapy has investigated the prognostic accuracy
of total tumour volume (TTV) [35]. After adjustment for
confounding factors, statistical analysis disclosed that patients
with TTV 50–200 cm3 [relative risk (RR): 1.74, P = 0.009],
200–500 cm3 [RR: 2.15, P = 0.006] and >500 cm3 [RR: 3.92,
P < 0.001] presented a higher mortality risk when compared
with patients with TTV <10 cm3, suggesting that the TTV
could represent a feasible prognostic predictor and a
potentially useful parameter for mortality risk stratiﬁcation.
Lastly, Kaseb et al. have hypothesised that insulin-like
growth factor-1 (IGF-1), a growth factor mainly produced by
the liver, could correlate with patients’ survival and hence
improve the prognostic ability of the CLIP score [36]. From the
analysis of IGF-1 concentrations and clinic-pathologic
parameters of 288 HCC patients, the authors observed that
IGF-1 was signiﬁcantly correlated with the clinic-pathologic
features: the CLIP criteria can, therefore, be extended to
include IGF-1 (I-CLIP) to improve prognostic stratiﬁcation of
HCC patients in clinical trials.
end points
In oncology practice, the primary goals of the clinicians are to
prolong the survival and alleviate the suffering of their patients.
As a consequence, demonstrating a meaningful beneﬁt in both
survival and symptom relief is the main answer clinicians
expect to ﬁnd, at least, in late-stage clinical research and should
be strongly considered in choosing clinical trials objectives.
In the case of trials with HCC patients, several
considerations need to be made. The dependency of HCC
patients’ survival upon liver disease rather than tumour
progression or treatment failure, the crucial role of liver
function in drug metabolism and tolerability and, ﬁnally, the
lack of therapeutic alternatives after the ﬁrst line form the
background that has to be considered in planning clinical
research in HCC.
Arguably, liver function is the most important factor
conditioning the choice of the end points for early-phase trials.
As cited above, a recent phase I trial recommended different
doses of sorafenib according to different degrees of liver
function [24]. The deﬁnition of the recommended dose based
only on the maximum-tolerated dose could be misleading in
patients with impaired liver function. Since both toxicity and
activity ultimately depend on circulating drug levels, though at
different levels respectively, it could be easily concluded that
pharmacokinetic end points should be necessarily evaluated in
phase I trials and that the recommended dose for phase II
should be based on accurate PK/PD modelling rather than
only on toxicity. However, toxicity still has to be taken into
account evaluating a new treatment in phase I trials, especially
in cases like sorafenib where a PK/organ function relationship
seems non-signiﬁcant [24, 28, 37] in contrast to the toxicity–
organ function relationship.
In late-stage clinical trials, OS, that is the time from the start
of the treatment (i.e. randomisation in the case of randomised
trials) to the death of the patient, is undoubtedly the optimal
parameter to estimate the beneﬁt and deﬁnitely will provide
clinicians with the answer to the question on how the
treatment prolongs the survival of treated patients. The
importance of OS as treatment goal is evident to patients and
physicians. Both, though mostly the patients have declared to
be willing to face adverse effects of treatment balanced by an
even small survival beneﬁt [38]. From a methodological
perspective, OS is as close to the ideal end point as it can be
considered easy to be measured in an error-free and unbiased
way [39, 40], it is objective and represents an unquestionable
beneﬁt for the patients. Therefore, it is considered the most
important end point. In fact, FDA has considered OS as a
direct, universally accepted measure of treatment beneﬁt and
preferred clinical trial end point when possible [41]. However,
the OS as end point of clinical trials can be hindered by some
disadvantages. The availability of effective therapies
administered after the trial impairs the ability of OS to catch a
real beneﬁt gain in a clinical trial [42], although this is not the
case in advanced HCC where no effective second-line
treatments exist in clinical practice. Similarly, the crossover
within a comparative trial can obscure a potential beneﬁt.
Other ‘OS as end point’ disadvantages comprise the large
number of patients and the long follow-up required that
recently hampered its more frequent use, at least for patients
without advanced disease. Finally and greatly interesting for
HCC trials, it has been argued that OS is not an optimal end
point in HCC because it is conditioned by competing causes of
death [6]. Theoretically, the latter point is not an obstacle to
the use of OS as principal end point and should be only taken
into account during the analysis of survival data in clinical
trials. Even in a tumour type where the prognosis is mostly
governed by other causes, like the liver disease in the HCC,
prolonging survival of patients remains the main goal of the
oncology treatment. One could argue that it is difﬁcult for OS
to catch a potential beneﬁt offered by a treatment, due to an
even modest rate of intercurrent deaths [43]. At the same time
one could conclude that whether the beneﬁt derived from the
anticancer treatment is not of such relevance to patient
survival (since it is not even reasonably possible to catch it) as
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the tremendous impact of intercurrent deaths, treating the
tumour is not as worthwhile as treating the competing causes
of death (i.e. liver disease in HCC).
However, an analysis of competing risks of death can be
successfully used to better estimate the beneﬁt of a treatment in
the case of alternative but plausible causes of death (i.e. liver
failure). Notably, this type of analysis will require an unrealistic
larger sample size than the OS analysis to permit an acceptable
power.
Quality-of-life analysis (QoL) and Time to Symptomatic
Progression require particular mention among the potential
end points. In particular, they respond to the other
fundamental question the clinician faces considering a
treatment implementation: ‘how will the treatment alleviate the
suffering of my patient?’.
However, differently from the OS, QoL and in general the
impact of a treatment on the symptoms burden is not easily
measurable. First, the questionnaires generally used to evaluate
QoL are not validated for patients with HCC. FACT-Hep [44]
and EORTC QLQ-C30 [45] are the most used and, at least the
ﬁrst, has been developed for patients with hepatobiliary
malignancies. Second it is very difﬁcult to judge when
worsening of symptoms is due to tumour progression rather
than to the underlying cirrhosis [6].
The drawbacks, described above, of OS as the primary end
point have prompted the recent, more frequent use of efﬁcacy
end points based on tumour assessments [6, 42].
Progression-free survival (PFS) and time to progression
(TTP) are the most used in advanced setting, while DFS and
time to recurrence (TTR) are used in adjuvant setting. The
main difference among the ‘survival’ end point and ‘time to’
end points is the type of the events are required for the
analysis. In case of DFS and PFS the events required include
both progression/recurrence and death from any cause. In TTP
and TTR the only event of interest is the progression or
recurrence whilst the patients dead at a certain time are
censored at that time. PFS and TTP are often used invariantly
in recent literature. However, PFS should be preferred from a
regulatory point of view due to its ability to catch fatal events
due to untoward treatment effects [46]. Overall PFS and TTP
might be attractive compared with OS because earlier to be
registered, requiring a lower number of patients and not being
prone to confounding factors as subsequent treatments
administered after the trial. Nevertheless, they can just
indirectly estimate a real clinical beneﬁt derived from a
treatment [47]. In contrast, on a theoretical basis, a trial
powered to catch a meaningful OS beneﬁt is also well powered
to catch a PFS or TTP beneﬁt whilst the opposite is never true.
Moreover, at least PFS, in hepatic-dysfunctioned HCC patients
where the life expectancy is often no longer than the time on
treatment due to the liver disease, is as prone as OS to the
confounding competing causes of death. Interestingly, the
results of a recent survey conducted by French oncologists and
methodologists have shown how the ‘optimal’ alternative end
points can vary according to the stage of HCC [48]. This
survey was extended to several types of gastrointestinal cancers:
with respect to HCC, DFS, PFS, local control and RR were
identiﬁed as preferred alternative end points in patients with
early disease. In case of advanced HCC and metastatic disease,
the preferred end point was PFS; the potential role of Quality
of Life (QoL) was also suggested, in line with some previous
observations and expert opinions [49, 50].
Moreover, all the tumour assessment based end points,
comprising Response Rate (RR) suffer from other issues. In
fact, they are largely dependent on tumour assessment interval
and on the tumour assessment criteria.
timing of radiological assessment
To minimize the risk of the ﬁrst potential bias, the re-
evaluation between the two arms has to be synchronized and
an interval of 6–8 weeks, symmetrically in both treatment arms
[6] could be recommended.
criteria for the assessment of radiological
response
Historically, tumour response to treatment was measured, from
a radiological point of view, by the World Health Organization
(WHO) criteria [51], and afterwards according to the Response
Evaluation Criteria in Solid Tumours (RECIST) [52]. The
WHO and RECIST criteria deﬁne standard methods for the
conversion of radiology images into measurable values to
assess the response to therapy in terms of tumour size [53].
Criteria for evaluating lesions have varied according to
different versions of the RECIST criteria [52, 54].
However, both WHO and RECIST criteria were developed in
the era of cytotoxics, thus considering only tumour shrinkage
due to cell death as a measure of antitumour activity [53]. Such
a measure can be misleading when applied to new targeted
anti-cancer drugs with a different mechanism of action, such
as the inhibition of angiogenesis or to other therapeutic
interventions, such as transarterial chemoembolization (TACE)
[52, 53]. These therapies may indeed determine tumour
devascularisation and necrosis, not being necessarily associated
with a reduction in size. In the landmark phase III SHARP
(Sorafenib Hepatocellular Carcinoma Assessment Randomised
Protocol) study, which assessed the efﬁcacy and safety of
sorafenib, a poor correlation between the clinical beneﬁt in
terms of survival and the RR according to the RECIST criteria
was shown [2]. On these bases, the AASLD proposed a formal
amendment of the RECIST criteria, which takes into
consideration the degree of tumour arterial enhancement: the
modiﬁed RECIST criteria (mRECIST) [53]. In addition, the
European Association for the Study of Liver Disease (EASL)
has deﬁned different criteria—the EASL criteria—for the
assessment of response [55]. Table 1 summarizes the
deﬁnitions of response according to the EASL, RECIST 1.1 and
mRECIST criteria [56].
The prognostic abilities of these criteria for the assessment
of response have been compared in different studies [56, 57].
Gilmore et al. determined the tumour response—using
RECIST 1.1, EASL and mRECIST criteria—in 83 HCC patients
treated with TACE as a palliative therapy [56]. Overall, a good
correlation between EASL and mRECIST was shown, with
overall response rates of 58% and 57%, and target lesion
responses of 74% and 73%, respectively. Conversely, a poor
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correlation for RECIST 1.1 criteria was reported, with overall
and target response rates of 7%. In addition, statistical analysis
disclosed a signiﬁcant association between OS and overall
response according to both the EASL (44% risk reduction of
death) and mRECIST (42%) criteria, while there was no
signiﬁcant association between OS and RECIST 1.1 response.
These results suggested that EASL and mRECIST overall
response rates may be predictors of survival and these criteria
might be used in preference to RECIST 1.1 criteria [56].
In another study, Edeline et al. retrospectively analysed 53
patients with advanced HCC treated with sorafenib, and
compared the response rates observed with the mRECIST and
the RECIST 1.1 criteria [57]. Patients who achieved an overall
response according to mRECIST criteria had a longer OS than
non-responding patients (median OS, 18 months and 8
months, respectively). In addition, among the 42 patients who
achieved SD according to RECIST, OS differed depending
upon mRECIST tumour response, with a median OS of 17
months, 10 months, and 4 months for patients who achieved
an overall response, a stable disease, or a progressive disease.
The authors concluded that mRECIST might be used for the
standard assessment of treatment activity in HCC patients in
clinical trials and clinical practice [57]. In addition, and
differing from what reported for locoregional therapies due to
the peculiar mechanism of action of targeted therapies, the
differences observed in vascularisation could reﬂect a real
biological change in the tumour, associated with clinically
meaningful implications for the patient even if the threshold
for response is not met [57].
Finally, the relative value of mRECIST when compared with
mWHO criteria has been evaluated by Finn et al. at the ASCO
2010 annual meeting [58]. Using the data from a phase II trial
with brivanib, a multikinase inhibitor, they found a relevant
discrepancy in the responses between mWHO (5 of 101) and
mRECIST (19 of 101) criteria. Moreover, 31 of 51 patients
experiencing a PD according to mWHO had SD according to
mRECIST and may have interrupted the treatment too early.
the importance of a radiological assessment
In recent years, the importance of a proper radiological
assessment in both the diagnosis and evaluation of treatments
for HCC, both in experimental trials and in clinical practice,
has been stressed in several publications [59–61]. Presently, the
imaging techniques commonly used for the diagnosis of HCC
are ultrasound (US), computed tomography (CT) and
MRI [59].
It is widely accepted that HCC emerges as a small nodule
composed of well-differentiated hepatocytes, and then
progresses at a heterogeneous rate into a larger nodule [61]. At
US, most small nodules appear hypoechoic, but some are
hyperechogenic due to a microsteatosis that may disappear
when tumour progresses. Major angiogenesis occurs between
10 and 20 mm, and most HCC >20 mm are intensely
hypervascular. Therefore, an intense contrast uptake in the
arterial phase followed by contrast washout in the delayed
venous phase should be used at dynamic imaging by CT/MRI
[61]. Arterial uptake may also be recognized by contrast
enhanced US (CEUS); however, CT or MRI currently
represents the most reliable method for the diagnosis of
HCC [61].
Imaging techniques do play a central role also in the
evaluation of treatment efﬁcacy. Follow-up examination with
CT or MRI is recommended every 3–6 months after surgical
resection, in order to identify possible recurrences [60, 61]. In
patients treated with locoregional therapies, the efﬁcacy of
imaging techniques to assess initial treatment success differs
with the tumour size [61]. In HCC <2 cm, any early
assessment after therapy may be misleading due to
inﬂammatory changes. In larger tumours, periprocedural
Table 1. Different radiological criteria (EASL, RECIST 1.1, and mRECIST) for the evaluation of response to anticancer treatments (reproduced from [56],
with permission)
EASL RECIST 1.1 mRECIST
Complete
response
(CR)
Disappearance of any intratumoural arterial
enhancement in all measurable arterially
enhancing liver lesions.
Disappearance of all target lesions (up to two
measurable liver lesions).
Disappearance of any intratumoural arterial
enhancement in all target lesions (up to
two measurable liver lesions).
Partial
response
(PR)
At least a 50% decrease in the sum of the
product of bi-dimensional diameters of
viable (enhancement in the arterial phase)
target lesions, taking as reference the
baseline sum of the diameters of target
lesions.
At least a 30% decrease in the sum of the
greatest unidimensional diameters of target
lesions, taking as reference the baseline
sum of the diameters of target lesions.
At least a 30% decrease in the sum of
unidimensional diameters of viable
(enhancement in the arterial phase) target
lesions, taking as reference the baseline
sum of the diameters of target lesions.
Stable disease
(SD)
Any cases that do not qualify for either
partial response or progressive disease.
Any cases that do not qualify for either
partial response or progressive disease.
Any cases that do not qualify for either
partial response or progressive disease.
Progressive
disease
(PD)
An increase of at least 25% in the sum of the
diameters of viable (enhancing) target
lesions, taking as reference the smallest
sum of the diameters of viable
(enhancing) target lesions recorded since
treatment started.
An increase of at least 20% in the sum of the
diameters of target lesions, taking as
reference the smallest sum of the diameters
of target lesions recorded since treatment
started.
An increase of at least 20% in the sum of the
diameters of viable (enhancing) target
lesions, taking as reference the smallest
sum of the diameters of viable (enhancing)
target lesions recorded since treatment
started.
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CEUS could be used to identify the non-ablated areas, while
CT or MRI are effective for follow-up monitoring, usually at 1
or 2 months after the procedure, every 3 months during the
ﬁrst 2 years, and every 4–6 months thereafter [61]. With
respect to sorafenib treatment, a recent study has evaluated the
role of MRI in the assessment of tumour response [62]. In
detail, MRI signal patterns were assessed in 21 advanced HCC
patients, at baseline and at short-term intervals thereafter
(survey time 2–65 weeks). Signal abnormalities were disclosed
by T1WI and T2WI in 15 of 21 patients. The predominant
tumour signal change was hyperintensity on both T1WI and
T2WI. Of note, most patients developed MRI signal changes
within 4 weeks of therapy, while two non-responders did not
show any signal alteration at follow-up. These ﬁndings, albeit
preliminary, could suggest that early MRI-based evaluation
could play a role in the evaluation of the efﬁcacy of sorafenib
treatment.
On these bases, US, CT and MRI should be considered
valuable and non-invasive imaging modalities for diagnosis of
HCC and the evaluation of treatment response in both a
clinical and an experimental setting. However, at present no
imaging technique is able to effectively diagnose small (<1 cm)
arterial enhancing lesions [59]; it has been suggested that
further improvement of imaging technologies—including
functional imaging such as elastography, perfusion imaging
and diffusion imaging—together with the development of new
contrast media has the potential to improve the detection and
characterization of these small tumours [59].
study design
As noted above, most of the recommendations in HCC made
even in the most updated guidelines are based on low strength
evidence. Similarly, most of the conclusions regarding the
efﬁcacy and toxicity of particular treatments in particular
populations [29, 63] are drawn from weak evidence.
Large, well-conducted, observational, studies might provide
complementary results to those collected in randomised
clinical trials (RCTs), as they assess the effectiveness of a given
treatment in patients encountered in day-to-day clinical
practice, potentially affected by different co-morbidities or
taking multiple treatments. In addition, well-designed
observational studies can help identify clinically relevant
differences among therapeutic options and collect information
on long-term drug effectiveness and safety [64]. Even when
well conducted they can nevertheless only suggest hypotheses,
they do not provide strong evidence for treatment beneﬁt.
Well-designed and conducted phase III RCTs represent the
strongest source of evidence in clinical research. Several factors
play a role in making the design of such trials difﬁcult in HCC
patients. In particular, as detailed above heterogeneity of HCC
patients due to profound differences in prognosis, related or
not to the tumour (disease extent and liver function), is one of
them. Although homogeneity in disease extent should be
warranted in the trial in order to allow proper comparison,
stratiﬁcation before randomisation, i.e. according to the CP
score and BCLC stage, can resolve most of this heterogeneity
without compromising the study power [25]. In this context,
randomisation is the only way to ensure the unbiased
distribution of all the known and unknown potential
confounding factors between the two arms. In fact, the use of
external controls (indirect comparison, historical controls or
large series) is restricted by the inability to control bias [65]
even when the comparison is made between apparently very
close populations [66]. As discussed above, this limits the role
of this kind of evidence, although it can provide useful
information to draw any informed conclusion or
recommendation to clinical practice.
concluding remarks
In 2012, HCC is still a major health problem. Although HCC
is only the sixth most common tumour, its mortality is
disproportionately high (third after lung and stomach) when
compared with similarly prevalent tumours. Prevention tools
and curative treatments are available only for a minority of
patients with HBV or non-infection-related HCC and with
local disease, respectively. Despite efforts have been made to
foster clinical research in HCC, dismal results have been
obtained until now and only one drug is available to patients
with advanced disease. The major problem in pursuing the
clinical beneﬁt demonstration for HCC patients is that most of
them suffer from underlying liver impairment potentially
affecting both tolerability and efﬁcacy of the treatment. An
ad hoc pathway of clinical development for new therapies
should be implemented with early trials conducted separately
in different populations of patients according to their liver
function (Figure 1). Pharmacodynamic/pharmacokinetic end
points should be used in phase I trials to deﬁne the
recommended dose for subsequent trials. However, phase I
trials still have to consider toxicity as an important end point
and should be designed to report it thoroughly. In the late-
stage trials, OS should be always considered as the most
important end point, and preferred as the primary one.
Alternative end points should also be considered as secondary
and reported along with OS. The competing causes of death,
indeed, do not impair the value of OS as treatment goal, nor
warrant an adequate surrogacy power to alternative end points
such as PFS and TTP. Moreover, these end points suffer from
potential bias related to the response evaluation, and the
Figure 1. Development pathway for clinical development of new
treatments in HCC.
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timing of tumour assessment. In fact, when reporting PFS and
TTP, the method of assessment and the assessment review
(central or independent or local) should also be explicitly
reported.
Finally, randomised trials with adequate randomisation
techniques, stratiﬁcation before randomisation and fair
comparison are needed to address the clinical problem of
physicians and patients facing up with HCC. Observational
studies are useful to collect information on a large scale, but in
the absence of evidence coming from randomised trials they
should be avoided and their resources should be used to build
robust evidence.
All the phases of investigations in HCC should proceed
contemporaneously. The urgency to gain favourable results in a
small proportion of patients is not worthwhile if it ultimately
leaves the clinical community in the doubt to treat the entire
population of patients without enough information.
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